Immunochemistry

HISCL sets new standards for diseases with increasing prevalence With our immunochemistry approach, we want to make a significant contribution to maintaining and improving patients' health. We are currently active in special areas such as dementia and liver disease, both of which are diseases with increasing prevalence. Early detection of Alzheimer’s disease with a simple blood test For a long time, the reliable detection of β-Amyloid was only possible from CSF or using imaging techniques (e.g. amyloid PET). Even in cases where these procedures are medically indicated, they are invasive or expensive. With the help of highly sensitive procedures such as the Sysmex HISCL immunoassay analyser, biomarkers for early detection of Alzheimer's disease - such as the β-Amyloid 1-42/ 1-40 ratio - can now be measured from blood samples. This makes diagnostics less risky, less complex and significantly more economical. Identification of patients in the early stages of liver disease Liver diseases kill some 300,000 people in Europe every year. Some of the biggest risk factors for liver disease are obesity, type 2 diabetes, and alcohol consumption, and as all of these are on the rise, cases of liver disease are likely to increase as well in the coming decades. With HISCL, and our unique liver biomarker M2BPGi*, we participate in the LIVERAIM project, one of the most important initiatives to date in the chronic liver disease research field. Overall, the project s’ goal is to set up a screening platform to detect cases of liver disease early on, so that patients can take steps to protect their liver before it’s too late. *not available in all regions